← Every company
SpringWorks Therapeutics Inc Patents
What SpringWorks Therapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
SWTX on carbonthat →Filings on file
51
Granted
13
Still pending
38
Filed under
7 names
51 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics Inc.2026-05-07Uchenna H. Iloeje | pending |
| CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSA61K 31/417, C07D 233/88, A61P 35/00, A61K 9/20, A61K 45/06, A61K2300/00Filed as SpringWorks Therapeutics, Inc.2025-10-07Kristin Patterson | pending |
| TREATMENT OF OVARIAN CANCER WITH NIROGACESTATA61K 31/4164, A61P 35/00, A61K 9/0053, A61K 9/20Filed as SpringWorks Therapeutics, Inc.2025-09-03Shinta CHENG | pending |
| DOSAGE FORMS OF MIRDAMETINIBA61K 31/166, A61P 25/00, A61P 35/00, A61J 3/07, A61K 9/0053, A61K 9/0095, A61K 9/10, A61K 9/1652, A61K 9/2054, A61K 9/4825, A61K 9/4833, A61K 9/4858, A61K 9/4866, C07C 259/10Filed as SpringWorks Therapeutics, Inc.2025-07-11Piero L. RUGGIERO | pending |
| IMPROVED MIRDAMETINIB TREATMENTFiled as SPRINGWORKS THERAPEUTICS, INC.2025-06-13UCHENNA H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61K 31/166, A61P 25/00, A61P 35/00Filed as SpringWorks Therapeutics Inc.2025-06-13Uchenna H. ILOEJE | pending |
| IMPROVED MIRDAMETINIB TREATMENTFiled as SPRINGWORKS THERAPEUTICS, INC.2025-06-13UCHENNA H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61K 31/166, A61P 25/00, A61P 35/00Filed as SpringWorks Therapeutics, Inc.2025-06-13Uchenna H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61K 31/166, A61P 25/00, A61P 35/00Filed as SpringWorks Therapeutics, Inc.2025-06-13Uchenna H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61K 31/166, A61P 25/00, A61P 35/00Filed as SpringWorks Therapeutics, Inc.2025-06-13Uchenna H. ILOEJE | pending |
| DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOFA61K 31/167, A61K 9/0056, A61K 9/16, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 9/2072Filed as SpringWorks Therapeutics, Inc.2025-06-11Kristin PATTERSON | pending |
| TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIBA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics, Inc.2025-03-18Uchenna H. ILOEJE | pending |
| SYNTHESIS OF NIROGACESTATC07D 233/88, C07D 263/44, C07C2602/10, A61K 31/417, C07B2200/07, C07C 227/08, C07C 227/18, C07C 227/26, C07C 229/10Filed as SpringWorks Therapeutics, Inc.2025-02-24Kristin PATTERSON | pending |
| NON-LINEAR DOSING OF MIRDAMETINIBA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics Inc.2025-02-14Uchenna H. ILOEJE | pending |
| IMPROVED MIRDAMETINIB TREATMENTFiled as SpringWorks Therapeutics, Inc.2025-02-05Uchenna H. ILOEJE | pending |
| CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOFC07C 259/10, A61K 9/0095, A61K 9/2013, A61K 9/2054, A61K 9/4825, A61K 9/4858, A61K 9/4866, C07B2200/13Filed as SpringWorks Therapeutics, Inc.2025-01-28Kristin PATTERSON | pending |
| TREATMENT OF MULTIPLE MYELOMAA61P 35/00, A61K 31/417, A61K 40/4215, A61K 40/31, A61K 40/11, G01N 33/57505, G01N 33/57585, A61K 31/4164, A61K 31/4439, A61K 31/55, A61K 35/17, A61K 45/06, C07K 16/2809, C07K 16/2878, C07K2317/31, C07K2317/732, C07K2319/40, A61K2300/00Filed as SpringWorks Therapeutics, Inc.2025-01-10Todd Webster SHEARER | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053Filed as SpringWorks Therapeutics, Inc.2024-10-10Uchenna H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053Filed as SpringWorks Therapeutics, Inc.2024-10-10Uchenna H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053Filed as SpringWorks Therapeutics, Inc2024-10-10Uchenna H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053Filed as SpringWorks Therapeutics, Inc.2024-10-10Uchenna H. ILOEJE | 12390430 |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053Filed as SpringWorks Therapeutics, Inc.2024-10-10Uchenna H. ILOEJE | pending |
| TREATMENTS WITH NIROGACESTATA61K 31/417, A61P 19/00, A61P 43/00, A61P 35/00, A61K 9/0053, A61K 31/4196, A61K 31/496, A61K 31/536, A61K 31/7048, A61K 45/06, A61K2300/00Filed as SpringWorks Therapeutics, Inc.2024-10-07Allison LIM | pending |
| FLUORINATED PHENYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONSA61K 31/166, C07C 211/55, A61K 31/192, A61K 31/216, A61K 31/245, A61K 31/4184, A61K 31/4523, A61K 31/519, C07C 229/58, C07C 251/54, C07C 291/04, A61K2300/00Filed as Springworks Therapeutics, Inc.2024-08-27Kristin PATTERSON | pending |
| Treatment of cutaneous neurofibromas with MirdametinibA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics, Inc.2024-08-27Uchenna H. Iloeje | pending |
| DOSAGE FORMS OF MIRDAMETINIBA61K 31/166, A61P 25/00, A61P 35/00, A61J 3/07, A61K 9/0053, A61K 9/0095, A61K 9/10, A61K 9/1652, A61K 9/2054, A61K 9/4825, A61K 9/4833, A61K 9/4858, A61K 9/4866, C07C 259/10Filed as SpringWorks Therapeutics, Inc.2024-07-08Piero L. RUGGIERO | 12383517 |
| MIRDAMETINIB TREATMENTFiled as SpringWorks Therapeutics, Inc.2024-06-25Uchenna H. ILOEJE | pending |
| COMPOSITIONS AND TREATMENTS WITH NIROGACESTATA61K 9/20, A61K 31/417, A61P 35/00, A61K 9/0053, A61K 9/48, A61K 9/50, A61K 45/06, A61K2300/00Filed as SpringWorks Therapeutics, Inc.2024-06-06Shinta CHENG | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics, Inc.2024-05-24Uchenna H. ILOEJE | 12257215 |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics, Inc.2024-05-24Uchenna H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as Springworks Therapeutics, Inc.2024-05-24Uchenna H. ILOEJE | 12220390 |
| BENZIMIDAZOLE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEADFiled as SPRINGWORKS THERAPEUTICS, INC.2024-05-16BRIAN LAWHORN | pending |
| TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEADFiled as SPRINGWORKS THERAPEUTICS, INC.2024-05-16BRIAN LAWHORN | pending |
| BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEADFiled as SPRINGWORKS THERAPEUTICS, INC.2024-05-16BRIAN LAWHORN | pending |
| COMPOSITIONS AND TREATMENTS WITH NIROGACESTATFiled as SpringWorks Therapeutics, Inc.2024-05-03Shinta CHENG | pending |
| TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIBA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics, Inc.2024-04-28Uchenna H. ILOEJE | 12295925 |
| COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOFC07D 487/04, A61P 35/00, A61K 31/519, A61K 31/529, A61K 31/549, A61K 31/551, C07D 471/04, C07D 487/18, C07D 519/00Filed as SPRINGWORKS THERAPEUTICS INC2024-04-12JIANWEI CHE | pending |
| TREATMENTS WITH NIROGACESTATA61K 31/417, A61P 19/00, A61P 43/00, A61P 35/00, A61K 9/0053, A61K 31/4196, A61K 31/496, A61K 31/536, A61K 31/7048, A61K 45/06, A61K2300/00Filed as SpringWorks Therapeutics, Inc.2024-04-02Allison Lim | 12138246 |
| METHODS OF TREATING MULTIPLE MYELOMAC07K 16/2878, A61P 35/00, A61K 31/4164, A61K 31/573, A61K2039/505, A61K2039/545Filed as SpringWorks Therapeutics, Inc.2024-03-22Phoenix Ho | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics, Inc.2024-03-19Uchenna H. ILOEJE | pending |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics, Inc.2024-03-19Uchenna H. ILOEJE | 12661330 |
| MIRDAMETINIB TREATMENTA61P 35/00, A61K 31/166, A61P 25/00, A61K 9/0053, A61K 31/216, A61K 45/06Filed as SpringWorks Therapeutics Inc.2024-03-19Uchenna H. ILOEJE | pending |
| DOSAGE FORMS OF MIRDAMETINIBA61K 31/166, A61P 25/00, A61P 35/00, A61J 3/07, A61K 9/0053, A61K 9/0095, A61K 9/10, A61K 9/1652, A61K 9/2054, A61K 9/4825, A61K 9/4833, A61K 9/4858, A61K 9/4866, C07C 259/10Filed as SpringWorks Therapeutics, Inc.2024-03-18Piero L. RUGGIERO | pending |
| DOSAGE FORMS OF MIRDAMETINIBA61K 31/166, A61P 25/00, A61P 35/00, A61J 3/07, A61K 9/0053, A61K 9/0095, A61K 9/10, A61K 9/1652, A61K 9/2054, A61K 9/4825, A61K 9/4833, A61K 9/4858, A61K 9/4866, C07C 259/10Filed as SpringWorks Therapeutics, Inc.2024-03-18Piero L. RUGGIERO | 12029711 |
| DOSAGE FORMS OF MIRDAMETINIBA61K 31/166, A61P 25/00, A61P 35/00, A61J 3/07, A61K 9/0053, A61K 9/0095, A61K 9/10, A61K 9/1652, A61K 9/2054, A61K 9/4825, A61K 9/4833, A61K 9/4858, A61K 9/4866, C07C 259/10Filed as SpringWorks Therapeutics, Inc.2024-03-18Piero L. RUGGIERO | pending |
| DOSAGE FORMS OF MIRDAMETINIBFiled as SPRINGWORKS THERAPEUTICS INC.2024-03-15PIERO L. RUGGIERO | pending |
| IMPROVED TREATMENT OF OVARIAN CANCER WITH NIROGACESTATA61K 31/417, A61P 19/00, A61K 9/0019, A61K 9/0053Filed as SpringWorks Therapeutics, Inc.2024-02-13Allison LIM | 12667555 |
| DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOFA61K 31/167, A61K 9/0056, A61K 9/16, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 9/2072Filed as SpringWorks Therapeutics, Inc.2024-01-31Kristin PATTERSON | 12090128 |
| CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOFC07C 259/10, A61K 9/0095, A61K 9/2013, A61K 9/2054, A61K 9/4825, A61K 9/4858, A61K 9/4866, C07B2200/13Filed as SpringWorks Therapeutics, Inc.2024-01-16Kristin PATTERSON | 12275688 |
| TREATMENTS WITH NIROGACESTATA61K 31/417, A61P 43/00, A61P 35/00, A61K 9/0053Filed as SpringWorks Therapeutics, Inc.2024-01-16Allison LIM | 12011435 |
| TREATMENTS WITH NIROGACESTATA61K 31/417, A61P 19/00, A61P 43/00, A61P 35/00, A61K 9/0053Filed as SpringWorks Therapeutics, Inc.2024-01-16Allison LIM | 12186305 |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.